Cytotoxicity Induced by Recombinant Human Tumor Necrosis Factor-α Dependent on the Types of Its Receptors on Canine Cells

Journal of Veterinary Medical Science

Volumn 60, Issue 8, 1998, Pages 889-895

  Aoki, Mica ^a   Sasaki, Nobuo ^b   Nomura, Koichi ^a   Katamoto, Hiromu ^a   Kubo, Kihei ^a   Kodama, Hiroshi ^a   Mukamoto, Masafumi ^a   Shimada, Terumasa ^a   Ohashi, Fumihito ^a  

^a Osaka Prefecture University   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

Author keywords

Canine cell; Cytotoxicity; rh TNF ; TNF receptor

Indexed keywords

RECOMBINANT PROTEIN; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL; ANIMAL DISEASE; ARTICLE; CELL CULTURE; CELL LINE; CELL SURVIVAL; CYTOLOGY; DOG; DOG DISEASE; DRUG EFFECT; HELA CELL; HUMAN; KIDNEY; KIDNEY TUMOR; LYMPHOCYTE; PATHOLOGY; PHYSIOLOGY; SARCOMA;

ANIMALS; CELL LINE; CELL SURVIVAL; DOG DISEASES; DOGS; HELA CELLS; HUMANS; KIDNEY; KIDNEY NEOPLASMS; LYMPHOCYTES; MAST-CELL SARCOMA; RECOMBINANT PROTEINS; TUMOR CELLS, CULTURED; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0032135371     PISSN: 09167250     EISSN: None     Source Type: Journal    
DOI: 10.1292/jvms.60.889     Document Type: Article

References (39)

1. Alley, M. C., Scudiero, D. A., Monks, A., Hursey, M. L., Czerwinski, M. J., Fine, D. L., Abbott, B. J., Mayo, J. G., Shoemaker, R. H. and Boyd, M. R. 1988. Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay. Cancer Res. 48: 589-601.
2. Barbara, J. A. J., Smith, W. B., Gamble, J. R., Ostade, X. V., Vandenabeele, P., Tavernier, J., Fiers, X., Vadas, M. A. and Lopez, A. J. 1994. Dissociation of TNF-α cytotoxic and proinflammatory activities by p55 receptor- and p75 receptor-selective TNFα mutants. EMBO J. 13. 843-850.
3. Beutler, B. and Cerami, A. 1988. Tumor necrosis, cachexia, shock, and inflammation: a common mediator. Annu. Rev. Biochem. 57: 505-518.
4. Brockhaus, M., Schoenfeld, H., Schlaeger, E., Hunziker, W., Lesslauer, O. and Loetscher, H. 1990. Identification of two types of tumor necrosis factor receptors on human cell lines by monoclonal antibodies. Proc. Natl. Acad. Sci. U.S.A. 87: 3127-3131.
5. Creasey, A. A., Doyle, L. V., Reynolads, J. T., Jung, T., Lin, L. S. and Vin, C. V. 1987. Biological effects of recombinant human tumor necrosis factor and its novel muteins on tumor and normal cell lines. Cancer Res. 47: 145-149.
6. Darling, D., Fraker, D. L., Jensen, J. C., Gorschboth C. M. and Norton, J. A. 1990. Cachectic effect of recombinant human tumor necrosis factor in rats. Cancer Res. 50: 4008-4013.
7. Dbaibo, G. S., Perry, D. K., Gamard, C. J., Platt, R., Poirier, G. G., Obeid, L. M. and Hannun, Y. A. 1997. Cytokine response modifier A (CrmA) inhibits ceramide formation in response to tumor necrosis factor-α: CrmA and Bcl-2 target distinct components in the apoptotic pathway. J. Exp. Med. 185: 481-490.
8. Erlichman, C. 1992. Pharmacology of Anticancer Drugs, pp. 317-337. In: The Basic Science of Oncology, 2nd ed. (Tannock, I.F. and Hill, R.P.), McGraw-Hill, Inc., New York:
9. Gehr, G., Gentz, R., Brockhaus, M. and Lotscher, M. 1992. Both tumor necrosis factor receptor types mediate proliferative signals in human mononuclear cell activation. J. Immunol. 149: 911-917.
10. Gutman, M., Inbar, M., Lev-Shlush, D., Abu-Abid, S., Mozes, M., Chaitchik, S., Meller, I. and Klausner, J. M. 1997. High dose tumor necrosis factor-α and melphalan administrated via isolated limb perfusion for advanced limb soft tissue sarcoma results in a >90% response rate and limb preservation. Cancer 79: 1129-1137.
11. Hohmann, H., Remy R., Brockhaus, M. and vonLoon, A. P. G. M. 1989. Two different cell types have different major receptors for human tumor necrosis factor. J. Biol. Chem. 264. 14927-14934.
12. Hsu, H., Shu, H., Pan, M. and Goeddel, D. V. 1996. TRDD-TRAF2 and TRDD-FADD interactions define two distinct TNF receptor 1 signal transduction pathways. Cell 84. 299-308.
13. Kalo, A. and Kawakami, M. 1990. Assay for tumor necrosis factor - Bioassay. Clin. Immunol. 22 (Suppl. 15) 78-85.
14. Knapp, D. W., Chan, T. C. K., Kuczek, T., Reagan, W. J. and Park, B. 1995. Evaluation of in vitro cytotoxicity of nonsteroidal anti-inflammatory drugs against canine tumor cells. Am. J. Vet. Rev. 56: 801-805.
15. Krosnick, J. A., Mule, J. J., McIntosh, J. K. and Rosenberg, S. A. 1989. Augmentation of antitumor efficacy by the combination of recombinant tumor necrosis factor and chemotherapeutic agents in vivo. Cancer Res. 49: 3729-3733.
16. Lewis, M., Tartaglia, L. A., Lee, A., Bennett, G. L., Rice, G. C., Wong, G. H. W., Chen, E. Y. and Goeddel, D. V. 1991. Cloning and expression of cDNAs for two distinct murine tumor necrosis factor receptors demonstrate one receptor is species specific. Proc. Natl. Acad. Sci. U.S.A. 88: 2830-2834.
17. Lasek, W., Giermasz, A., Kuc. K., Wankowicz, A., Feleszko, W., Golab, J., Zagozdzon, R., Stoklosa, T. and Jakobisiak, M. 1996. Potentiation of the anti-tumor effect of ActD by TNFα in mice: corelation between in vitro and in vivo results. Int. J. Cancer 66: 374-379.
18. Lienard, D., Ewalenko, P., Delmotte, J., Renard, N. and Lejeune, F. J. 1992. High-dose recombinant tumor necrosis factor alpha in combination with interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma. J. Clin. Oncol. 10: 52-60.
19. Loetscher, H., Pan, Y. E., Lahm, H., Gentz, R., Brockhaus, M., Tabuchi, H. and Lesslauer, W. 1990. Molecular cloning and expression of the human 55 kd tumor necrosis factor receptor. Cell 61: 351-359.
20. Maehara, Y., Kohnoe, S., Sakaguchi, Y., Emi, Y., Kusumoto, T., Miyamoto, K., Fukuchi, K. and Sugimachi, K. 1990. Chemosensitivity of human tumors in vitro evaluated by the succinate dehydrogenase inhibition (SDI) test. Saishin-Igaku 45: 136-146 (in Japanese with English summary).
21. Malaviya, R., Ikeda, T., Ross, E. and Abraham, S. N. 1996. Mast cell modulation of neutrophil influx and bacterial clearanace at sites of infection through TNF-α. Nature (Lond.) 381: 77-80.
22. Moore, A. S., Theilen, G. H., Newell, A. D., Madewell, B. R. and Rudolf, A. R. 1991. Preclinical study of sequential tumor necrosis factor and interleukin 2 in the treatment of spontaneous canine neoplasms. Cancer Res. 51: 233-238.
23. Mosmann, T. 1983. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J. Immunol. Methods 65: 55-63.
24. Nakada, Y., Maeda, S., Miyamori, M., Takahashi, T., Moriyama, A. and Kuwabara, M. 1997. Therapeutic effect of endogenous tumor necrosis factor induction on mammary tumors in cats. J. Jpn. Vet. Med. Assoc. 50: 161-164 (in Japanese with English summary).
25. Negrier, M.S., Pourreau, C. N., Palmer, P. A., Ranchere, J. Y., Mercatello, A., Viens, P., Blaise, D., Jasmin, C., Misset, J. L., Franks, C. R., Maraninchi, D. and Philip, T. 1992. Phase I trial of recombinant interleukin-2 followed by recombinant tumor necrosis factor in patients with metastatic cancer. J. Immunother. 11: 93-102.
26. Nicoletti, I., Migliorati, G., Pagliacci, M. C. and Riccardi, C. 1991. A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. J. Immunol. Methods 139: 271-279.
27. Rimstad, E., Reubel, G. H., Dean, G. A., Higgins, J . and Pedersen, N. C. 1995. Cloning, expression and characterizaion of biologically active feline tumor necrosis factor-α. Vet. Immunol. Immunopathol. 45 297-310.
28. Sakaguchi, Y., Makino, M., Kaneko, T., Stephens, L. C., Strebel, F. R., Danhauser, L. L., Jenkins, G. N. and Bull, M. C. 1994. Therapeutic efficacy of long duration-low temperature whole body hypertheramia when combined with tumor necrosis factor and carboplatin in rats. Cancer Res. 54: 2223-2227.
29. Schmidt-walf, G. D. and Schmidt-Wolf G. H. 1995. Cytokines and gene therapy. Imunol. Today 16: 173-175.
30. Shimomura, K., Manda, T., Mukumoto, S., Kobayashi, K., Nakano, K. and Mori, J. 1988 Recombinant human turmor necrosis factor-α: thrombus formation is a cause of anti-tumor activity. Int. J. Cancer 41: 243-247.
31. Tartaglia, L. A., Wever, R. F., Figari, I. S., Reynolds, C. Palladino, M. A. Jr. and Goeddel, D. V. 1991. The two different receptors for tumor necrosis factor mediate distinct cellular responses. Proc. Natl. Acad. Sci. U.S.A. 88: 9292-9296.
32. Tracey, K. J., Beutler, B., Lowry, S. F., Merryweather, J., Wlope, S., Milsark, I. W., Hariri, R. J., Fahey III, T.J., Zentella, A., Albert, J. D., Shires, T. and Cerami, A. 1986. Shock and tissue injury induced by recombinant human cachectin. Science 234: 470-473.
33. Watanabe, N., Yamada, N. and Maeda, M. 1994. Recombinant human tumor necrosis factor causes regression in patients with advanced malignancies. Oncology 51: 360-365.
34. Watanabe, N., Okamoto, T., Tsuji, N., Sasaki, H., Akiyama, S., Kobayashi, D., Sato, T., Yamauchi, N. and Niitsu, Y. 1995. Reversal of tumor necrosis factor resistance in tumor cells by adriamycin via suppression of intracellular resistance factors. Jpn. J. Cancer Res. 86: 395-399.
35. Wong, G. H. W., Elwell, J. H. Oberley, L. W. and Goeddel. D. V. 1989. Manganous Superoxide dismutase is essential for cellular resistance to cytotoxicity of tumor necrosis factor. Cell 58: 923-931.
36. Yamaue, H., Tanimura, H., Noguchi, K., Hotta, T., Tani, M., Tsunoda, T., Iwahashi, M., Tamai, M. and Iwakura, S. 1992. Chemosensitivity testing of fresh human gastric cancer with highly purified tumor cells using the MTT assay. Br. J. Cancer 66. 794-799.
37. Yang, D., Satoh, M. and Ueda, H. 1994. Activation of tumor infiltrating macrophages by a synthetic lipid A analog and its implication in anti-tumor effect. Cancer Immunol. Immunother. 38 287-293.
38. Yamauchi, N., Kuriyama, H., Watanabe, N., Neda, H., Maeda, M. and Niitsu, Y. 1989. Intracellular hydroxyl radical production induced by recombinant human tumor necrosis factor and its implication in the killing of tumor cells in vitro. Cancer Res. 49: 1671-1675.
39. Zucher, K., Lu, P., Fuller, L., Asthana, D., Esquenazi, V. and Miller J. 1994. Cloning and expression of the cDNA for canine tumor necrosis factor-α in E. Coli. Lymphokine and Cytokine Res. 13: 191-196.